BioCentury | Feb 11, 2019
Distillery Therapeutics

Infectious disease

...the efficacy and safety of the compound in mouse models with chronic, severe Buruli ulcers. Qurient Co. Ltd....
BioCentury | Jul 10, 2018
Distillery Therapeutics

Infectious disease

...treatment. Next steps could include optimizing and testing the inhibitor in additional models of TB. Qurient Co. Ltd....
BioCentury | Dec 15, 2016
Targets & Mechanisms

Keeping the Gas off AXL

...Phase II BerGenBio A/S; Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) BGB324 AXL inhibitor NSCLC; AML Phase I Qurient Co. Ltd....
BioCentury | Apr 4, 2016
Finance

Fundamental reset

...gain of 18%, led by a 149% rise in the market value of Korean biotech Qurient Co. Ltd....
...NASDAQ:CRVS) 3/22/16 $70.5 $306.1 $295.9 -3% Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) 3/2/16 $52.8 $208.5 $231.4 11% Qurient Co. Ltd....
BioCentury | Mar 21, 2016
Finance

Multiples in Korea

...Venture Fund is looking at significant paper gains after a recent IPO by portfolio company Qurient Co. Ltd....
...biotechs tend to jump straight from government funding to a public listing. On Feb. 29, Qurient...
...The value of shares in those rounds was not disclosed, but CEO Kiyean Nam said Qurient's...
BioCentury | Mar 21, 2016
Product Development

Korea rising

...$1 billion in translational and clinical research grants (see "Korea Funds"). Kiyean Nam, CEO of Qurient Co. Ltd....
...structure of the three investment funds reflects the government's understanding that drug development takes time. Qurient...
...Korea and other research facilities. Q203 was discovered at the institute and licensed to Qurient. Qurient's...
BioCentury | Mar 21, 2016
Financial News

Qurient completes IPO

Qurient Co. Ltd. (KOSDAQ:115180), Seongnam, South Korea Business: Infectious, Inflammation, Cancer Date completed: 2016-02-29 Type: IPO Raised: W32.5 billion ($26 million) Shares: 1.5 million Price: W21,000 Shares after offering: 7.2 million Underwriter: Korea Investment &...
BioCentury | Jul 13, 2015
Company News

Lead Discovery Center, Qurient deal

...Lead Discovery Center (LDC) granted Qurient exclusive, worldwide rights to develop cyclin dependent kinase 7 (CDK7...
...viral infection. LDC will receive an undisclosed upfront payment and is eligible for development milestones. Qurient...
...will guide and fund development until completion of Phase II testing, after which LDC said Qurient...
BioCentury | Mar 13, 2014
Cover Story

Killer targets in metastasis

...Bonn . The series of molecules described in the paper, including LDC1267, is licensed to Qurient Co. Ltd....
...Clinical trials in acute myelogenous leukemia (AML) and lung cancer are planned for this year. Qurient...
...Innsbruck , Innsbruck, Austria Meryx Inc. , Chapel Hill, N.C. Oribase Pharma , Montpellier, France Qurient Co. Ltd....
BioCentury | Mar 13, 2014
Distillery Therapeutics

Indication: Cancer

...Pharmaceuticals Inc. and partner Oribase Pharma have AXL inhibitors in preclinical development to treat cancer. Qurient Co. Ltd....
...Max Planck Institute of Biochemistry covering a chemical series of TAM receptor inhibitors; licensed to Qurient...
Items per page:
1 - 10 of 16
BioCentury | Feb 11, 2019
Distillery Therapeutics

Infectious disease

...the efficacy and safety of the compound in mouse models with chronic, severe Buruli ulcers. Qurient Co. Ltd....
BioCentury | Jul 10, 2018
Distillery Therapeutics

Infectious disease

...treatment. Next steps could include optimizing and testing the inhibitor in additional models of TB. Qurient Co. Ltd....
BioCentury | Dec 15, 2016
Targets & Mechanisms

Keeping the Gas off AXL

...Phase II BerGenBio A/S; Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) BGB324 AXL inhibitor NSCLC; AML Phase I Qurient Co. Ltd....
BioCentury | Apr 4, 2016
Finance

Fundamental reset

...gain of 18%, led by a 149% rise in the market value of Korean biotech Qurient Co. Ltd....
...NASDAQ:CRVS) 3/22/16 $70.5 $306.1 $295.9 -3% Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) 3/2/16 $52.8 $208.5 $231.4 11% Qurient Co. Ltd....
BioCentury | Mar 21, 2016
Finance

Multiples in Korea

...Venture Fund is looking at significant paper gains after a recent IPO by portfolio company Qurient Co. Ltd....
...biotechs tend to jump straight from government funding to a public listing. On Feb. 29, Qurient...
...The value of shares in those rounds was not disclosed, but CEO Kiyean Nam said Qurient's...
BioCentury | Mar 21, 2016
Product Development

Korea rising

...$1 billion in translational and clinical research grants (see "Korea Funds"). Kiyean Nam, CEO of Qurient Co. Ltd....
...structure of the three investment funds reflects the government's understanding that drug development takes time. Qurient...
...Korea and other research facilities. Q203 was discovered at the institute and licensed to Qurient. Qurient's...
BioCentury | Mar 21, 2016
Financial News

Qurient completes IPO

Qurient Co. Ltd. (KOSDAQ:115180), Seongnam, South Korea Business: Infectious, Inflammation, Cancer Date completed: 2016-02-29 Type: IPO Raised: W32.5 billion ($26 million) Shares: 1.5 million Price: W21,000 Shares after offering: 7.2 million Underwriter: Korea Investment &...
BioCentury | Jul 13, 2015
Company News

Lead Discovery Center, Qurient deal

...Lead Discovery Center (LDC) granted Qurient exclusive, worldwide rights to develop cyclin dependent kinase 7 (CDK7...
...viral infection. LDC will receive an undisclosed upfront payment and is eligible for development milestones. Qurient...
...will guide and fund development until completion of Phase II testing, after which LDC said Qurient...
BioCentury | Mar 13, 2014
Cover Story

Killer targets in metastasis

...Bonn . The series of molecules described in the paper, including LDC1267, is licensed to Qurient Co. Ltd....
...Clinical trials in acute myelogenous leukemia (AML) and lung cancer are planned for this year. Qurient...
...Innsbruck , Innsbruck, Austria Meryx Inc. , Chapel Hill, N.C. Oribase Pharma , Montpellier, France Qurient Co. Ltd....
BioCentury | Mar 13, 2014
Distillery Therapeutics

Indication: Cancer

...Pharmaceuticals Inc. and partner Oribase Pharma have AXL inhibitors in preclinical development to treat cancer. Qurient Co. Ltd....
...Max Planck Institute of Biochemistry covering a chemical series of TAM receptor inhibitors; licensed to Qurient...
Items per page:
1 - 10 of 16